Influence of the Fatty Acid Metabolism on the Mode of Action of a Cisplatin(IV) Complex with Phenylbutyrate as Axial Ligands

For a variety of cancer types, platinum compounds are still among the best treatment options. However, their application is limited by side effects and drug resistance. Consequently, multi-targeted platinum(IV) prodrugs that target specific traits of the malignant tissue are interesting new candidates. Recently, cisPt(PhB)2 was synthesized which, upon reduction in the malignant tissue, releases phenylbutyrate (PhB), a metabolically active fatty acid analog, in addition to cisplatin. In this study, we in-depth investigated the anticancer properties of this new complex in cell culture and in mouse allograft experiments. CisPt(PhB)2 showed a distinctly improved anticancer activity compared to cisplatin as well as to PhB alone and was able to overcome various frequently occurring drug resistance mechanisms. Furthermore, we observed that differences in the cellular fatty acid metabolism and mitochondrial activity distinctly impacted the drug’s mode of action. Subsequent analyses revealed that “Warburg-like” cells, which are characterized by deficient mitochondrial function and fatty acid catabolism, are less capable of coping with cisPt(PhB)2 leading to rapid induction of a non-apoptotic form of cell death. Summarizing, cisPt(PhB)2 is a new orally applicable platinum(IV) prodrug with promising activity especially against cisplatin-resistant cancer cells with “Warburg-like” properties.

[1]  Soo-Youl Kim,et al.  Cancer depends on fatty acids for ATP production: a possible link between cancer and obesity. , 2022, Seminars in cancer biology.

[2]  G. Misso,et al.  Bioactivity and Development of Small Non-Platinum Metal-Based Chemotherapeutics , 2022, Pharmaceutics.

[3]  Weiyu He,et al.  Multifunctional platinum(IV) complex bearing HDAC inhibitor and biotin moiety exhibits prominent cytotoxicity and tumor-targeting ability. , 2022, Dalton transactions.

[4]  S. Chandrasekaran,et al.  Metabolism, HDACs, and HDAC Inhibitors: A Systems Biology Perspective , 2021, Metabolites.

[5]  A. Schintlmeister,et al.  Albumin-targeting of an oxaliplatin-releasing platinum(iv) prodrug results in pronounced anticancer activity due to endocytotic drug uptake in vivo , 2021, Chemical science.

[6]  I. Turel,et al.  Metal- and metalloid-based compounds to target and reverse cancer multidrug resistance. , 2021, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[7]  G. Natile,et al.  Interference between copper transport systems and platinum drugs. , 2021, Seminars in cancer biology.

[8]  W. Ang,et al.  Strategy for Traceless Codrug Delivery with Platinum(IV) Prodrug Complexes Using Self-Immolative Linkers. , 2021, Inorganic chemistry.

[9]  D. Gibson.  Platinum(IV) anticancer agents; are we en route to the holy grail or to a dead end? , 2021, Journal of inorganic biochemistry.

[10]  H. Crossland,et al.  Phenylbutyrate, a branched‐chain amino acid keto dehydrogenase activator, promotes branched‐chain amino acid metabolism and induces muscle catabolism in C2C12 cells , 2020, Experimental physiology.

[11]  P. Vaupel,et al.  Revisiting the Warburg effect: historical dogma versus current understanding , 2020, The Journal of physiology.

[12]  M. Preusser,et al.  Targeted Therapy Recommendations for Therapy Refractory Solid Tumors—Data from the Real-World Precision Medicine Platform MONDTI , 2020, Journal of personalized medicine.

[13]  M. Devereux,et al.  Pt(IV) pro-drugs with an axial HDAC inhibitor demonstrate multimodal mechanisms involving DNA damage and apoptosis independent of cisplatin resistance in A2780/A2780cis cells. , 2020, Journal of inorganic biochemistry.

[14]  A. Garufi,et al.  PBA Preferentially Impairs Cell Survival of Glioblastomas Carrying mutp53 by Reducing Its Expression Level, Stabilizing wtp53, Downregulating the Mevalonate Kinase and Dysregulating UPR , 2020, Biomolecules.

[15]  S. Spiegel,et al.  Functional analysis of molecular and pharmacological modulators of mitochondrial fatty acid oxidation , 2020, Scientific Reports.

[16]  Andrés Clemente-Blanco,et al.  Cell Cycle and DNA Repair Regulation in the Damage Response: Protein Phosphatases Take Over the Reins , 2020, International journal of molecular sciences.

[17]  T. Hambley.  Transporter and protease mediated delivery of platinum complexes for precision oncology , 2019, JBIC Journal of Biological Inorganic Chemistry.

[18]  K. Gu,et al.  Oxaliplatin-Based Regimen is Superior to Cisplatin-Based Regimen in Tumour Remission as First-line Chemotherapy for Advanced Gastric Cancer: A Meta-Analysis , 2019, Journal of Cancer.

[19]  W. Berger,et al.  CHAPTER 12. Challenges and Chances in the Preclinical to Clinical Translation of Anticancer Metallodrugs , 2019, Metal-based Anticancer Agents.

[20]  C. Marmion,et al.  Toward Multi-Targeted Platinum and Ruthenium Drugs-A New Paradigm in Cancer Drug Treatment Regimens? , 2019, Chemical reviews.

[21]  Farzane Sivandzade,et al.  Analysis of the Mitochondrial Membrane Potential Using the Cationic JC-1 Dye as a Sensitive Fluorescent Probe. , 2019, Bio-protocol.

[22]  K. Alzoubi,et al.  The effect of combined treatment with sodium phenylbutyrate and cisplatin, erlotinib, or gefitinib on resistant NSCLC cells , 2018, Clinical pharmacology : advances and applications.

[23]  Ajit S. Divakaruni,et al.  Etomoxir Inhibits Macrophage Polarization by Disrupting CoA Homeostasis. , 2018, Cell metabolism.

[24]  C. June,et al.  The CPT1a inhibitor, etomoxir induces severe oxidative stress at commonly used concentrations , 2018, Scientific Reports.

[25]  Y. Kimata,et al.  4-Phenylbutyrate suppresses the unfolded protein response without restoring protein folding in Saccharomyces cerevisiae , 2018, FEMS yeast research.

[26]  K. Tam,et al.  Phenyl butyrate inhibits pyruvate dehydrogenase kinase 1 and contributes to its anti‐cancer effect , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[27]  M. Al-Keilani,et al.  Potential of Phenylbutyrate as Adjuvant Chemotherapy: An Overview of Cellular and Molecular Anticancer Mechanisms. , 2017, Chemical research in toxicology.

[28]  M. Eberlin,et al.  Triacsin C reduces lipid droplet formation and induces mitochondrial biogenesis in primary rat hepatocytes , 2017, Journal of Bioenergetics and Biomembranes.

[29]  L. Sharma,et al.  Chemical Chaperone 4-Phenyl Butyric Acid (4-PBA) Reduces Hepatocellular Lipid Accumulation and Lipotoxicity Through Induction of Autophagy , 2017 .

[30]  R. Wanders,et al.  Identification of enzymes involved in oxidation of phenylbutyrate , 2017, Journal of Lipid Research.

[31]  K. Morten,et al.  The Warburg effect: 80 years on , 2016, Biochemical Society transactions.

[32]  M. Simon,et al.  BODIPY 493/503 Staining of Neutral Lipid Droplets for Microscopy and Quantification by Flow Cytometry. , 2016, Bio-protocol.

[33]  V. Brabec,et al.  Pt(iv) derivatives of cisplatin and oxaliplatin with phenylbutyrate axial ligands are potent cytotoxic agents that act by several mechanisms of action† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c5sc04205d , 2016, Chemical science.

[34]  R. Cairns.  Drivers of the Warburg phenotype. , 2015, Cancer journal.

[35]  Chunfa Huang,et al.  Lipid Metabolism, Apoptosis and Cancer Therapy , 2015, International journal of molecular sciences.

[36]  E. Makarov,et al.  [Histone deacetylase inhibitors cause the TP53-dependent induction of p21/Waf1 in tumor cells carrying mutations in TP53]. , 2015, Tsitologiia.

[37]  D. Richardson,et al.  Unraveling the mysteries of serum albumin—more than just a serum protein , 2014, Front. Physiol..

[38]  Alexis Gautreau,et al.  Quantitative and unbiased analysis of directional persistence in cell migration , 2014, Nature Protocols.

[39]  G. Cline,et al.  Functional polarization of tumour-associated macrophages by tumour-derived lactic acid , 2014, Nature.

[40]  O. Krämer,et al.  p53-dependent and p53-independent anticancer effects of different histone deacetylase inhibitors , 2013, British Journal of Cancer.

[41]  W. Berger,et al.  Unsymmetric mono- and dinuclear platinum(IV) complexes featuring an ethylene glycol moiety: synthesis, characterization, and biological activity. , 2012, Journal of medicinal chemistry.

[42]  J. Vockley,et al.  Evidence for involvement of medium chain acyl-CoA dehydrogenase in the metabolism of phenylbutyrate. , 2012, Molecular genetics and metabolism.

[43]  V. Adam,et al.  The synergistic effects of DNA-targeted chemotherapeutics and histone deacetylase inhibitors as therapeutic strategies for cancer treatment. , 2012, Current medicinal chemistry.

[44]  W. Berger,et al.  Anticancer activity of metal complexes: involvement of redox processes. , 2011, Antioxidants & redox signaling.

[45]  E. Wiemer,et al.  Drug transporters of platinum-based anticancer agents and their clinical significance. , 2011, Drug resistance updates.

[46]  U. Vaishampayan,et al.  Satraplatin: leading the new generation of oral platinum agents , 2009, Expert opinion on investigational drugs.

[47]  W. Berger,et al.  Resistance against novel anticancer metal compounds: differences and similarities. , 2008, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[48]  M. Ljungman,et al.  Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin , 2008, Molecular Cancer.

[49]  J. Roth,et al.  Sodium 4-phenylbutyrate acts as a chemical chaperone on misfolded myocilin to rescue cells from endoplasmic reticulum stress and apoptosis. , 2007, Investigative Ophthalmology and Visual Science.

[50]  C. Schmitt,et al.  Apoptosis and Cancer Therapy , 2007 .

[51]  S. Kaufmann,et al.  Induction of apoptosis in malignant B cells by phenylbutyrate or phenylacetate in combination with chemotherapeutic agents. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[52]  R. Santucci,et al.  Effects of phenylbutyrate on proliferation and apoptosis in human prostate cancer cells in vitro and in vivo. , 1999, International journal of oncology.

[53]  R. Unger,et al.  Fatty acid-induced β cell apoptosis: A link between obesity and diabetes , 1998 .

[54]  J. Horowitz,et al.  Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. , 1996, Biochemical pharmacology.

[55]  J. Nelson,et al.  Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.